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ABSTRACT
Objective: Downbeat nystagmus (DBN) is the most frequent form of acquired persisting fixation nys-
tagmuswith different symptoms such as unsteadiness of gait, postural instability, and blurred vision
with reduced visual acuity (VA) and oscillopsia. However, different symptomatic therapeutic princi-
ples are required, such as 3,4-diaminopyridine and 4-aminopyridine, that effectively suppress DBN.
Chlorzoxazone (CHZ) is a nonselective activator of small conductance calcium-activated potassium
(SK) channels that modifies the activity of cerebellar Purkinje cells. We evaluated the effects of this
agent on DBN in an observational proof-of-concept pilot study.
Methods: Ten patients received CHZ 500mg 3 times a day for 1 or 2 weeks. Slow-phase velocity
of DBN, VA, postural sway, and the drug’s side effects were evaluated. Recordings were con-
ducted at baseline, 90 minutes after first administration, and after 1 or 2 weeks.
Results: Mean slow-phase velocity significantly decreased from a baseline of 2.74°/s 6 2.00 to
2.29°/s 6 2.12 (mean 6 SD) 90 minutes after first administration and to 2.04°/s 6 2.24 (p ,
0.001; post hoc both p 5 0.024) after long-term treatment. VA significantly increased and pos-
tural sway in posturography showed a tendency to decrease on medication. Fifty percent of
patients did not report any side effects. The most common reported side effect was abdominal
discomfort and dizziness.
Conclusions: The treatment with the SK-channel activator CHZ is a potentially new therapeutic
agent for the symptomatic treatment of DBN.
Classification of evidence: This study providesClass IV evidence that CHZ500mg3 times a daymay
improve eye movements and visual fixation in patients with DBN. Neurology 2013;81:1152–1158
GLOSSARY
4-AP 5 4-aminopyridine; CHZ 5 chlorzoxazone; 3,4-DAP 5 3,4-diaminopyridine; DBN 5 downbeat nystagmus; EA2 5
episodic ataxia type 2; PC5 Purkinje cell; SK5 small conductance calcium-activated potassium; SPV5 slow-phase velocity;
VA 5 visual acuity.
Downbeat nystagmus (DBN) is the most frequent form of acquired persisting fixation nystag-
mus.1–3 The most common symptoms are unsteadiness of gait, postural instability, blurred vision
with reduced visual acuity (VA), and vertical oscillopsia.1,2 DBN is most often caused by impaired
function of the cerebellar flocculus/paraflocculus.4 The etiology is diverse. In approximately 40% of
patients, no underlying pathology can be found.3 Of the different medications that have been used
to treat DBN,5 GABAergic, glutamatergic, and cholinergic drugs showed only moderate success.5
However, 3,4-diaminopyridine (3,4-DAP) and 4-aminopyridine (4-AP) effectively suppress DBN.5
The small conductance calcium-activated potassium (SK) channel activator chlorzoxazone
(CHZ) reduced burst-like firing and thereby decreased irregular Purkinje cell (PC) firing in P/Q
calcium-channel CACNA1aS218L mutants.5–8 A mechanism similar to that of Kv1.5 potassium-
channel blockers5–7 is assumed for the effects of aminopyridines in episodic ataxia type 2 (EA2).
CHZ has already been used as a centrally acting agent for painful musculoskeletal conditions and
muscle spasm,9,10 and is an over-the-counter drug approved by the US Food and Drug Adminis-
tration10 (for reference, see http://www.drugs.com/pro/chlorzoxazone.html). Based on the
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above-mentioned theoretical and pharmacologic
effect and in particular its action on PCs, the
effectiveness in patients with DBN was tested.
METHODS Level of evidence. The aim of this Class IV evi-
dence study was to evaluate the effect of CHZ 500 mg 3 times a
day orally in terms of eye movements, postural sway, and visual
fixation in patients with DBN.
Standard protocol approvals, registration, and patient
consents. This pilot trial was only an observational study. All pa-
tients gave their informed consent for the compassionate use of CHZ.
Concept of the pilot trial. Ten patients (aged 48–78 years, 5
females; for further details, see table 1) received 500 mg of CHZ 3
times a day for 1 or 2 weeks. Measurements were conducted at
baseline, after first drug administration, and after 1 to 2 weeks of
treatment. Measurements were performed 90 minutes after first
administration as peak levels of CHZ may be reached approxi-
mately 1 to 2 hours after oral administration.11 After this first dose
of the medication, the patients took another tablet in the evening;
from day 2 of the observational period, the patients had the full
dosage of CHZ 500 mg 3 times a day. Eye movements were
recorded with 3-dimensional video-oculography (EyeSeeCam)
(see reference 12). VA was measured using the Snellen chart
positioned at a distance of 6 m and was specified as a decimal.
Thus, optimal VA is 1.0. Posturographic measurements were
conducted in the upright position with eyes open and head
extended backward (30°). The 2 conditions included standing
either on firm ground (condition 1) or on a slab of foam rubber
(condition 2) (see reference 13). The body sway of 30 seconds of
the posturographic measurement provided the sway path values
(m/min). For safety reasons, blood testing of liver enzymes,
sodium, potassium, creatinine, and urea was performed. The
patients used the 28-item Vestibular Disorders Activities of Daily
Living Scale14 to determine their functional burden of disease on a
10-point scale at baseline and during treatment.
Statistical analysis. Figures were designed using Prism version
5 (GraphPad Software, Inc., La Jolla, CA). Statistical analysis was
done using SPSS version 20 (IBM Corp., Armonk, NY). Data
were not normally distributed; hence, nonparametric statistical
tests were performed. To look for differences between baseline
and the 2 measurements under medication, the Friedman test
with x2 test statistics was applied. For individual post hoc
comparisons, the nonparametric Wilcoxon test statistics with
Bonferroni correction were applied. In the eye-movement data,
slow-phase velocity (SPV) of vertical eye movements was the
dependent variable. DBN indicated by mean SPV (degrees/s) ap-
pears as a positive value, whereas the absence of DBN is a near zero
value. For VA and postural sway, the same statistical analysis as in
SPV was applied. The significance level was set to 5%. Patients who
did not complete the long-term treatment were not included in the
baseline data for the long-term treatment analysis.
RESULTS Effects of CHZ on SPV of DBN. Mean SPV
decreased from baseline of 2.74°/s 6 2.00 (mean 6
SD) to 2.29°/s6 2.12 after the first administration of
CHZ 500 mg and from 3.09°/s 6 2.19 to 2.04°/s 6
2.24 after long-term treatment. There was a significant
overall decrease (Friedman test with x2 statistics 5
8.86, p , 0.001, n 5 7) with a significant post hoc
difference between baseline and 90 minutes after first
administration (p 5 0.024) as well as after long-term
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treatment (p , 0.001). The patients showed a mean
DSPV of 28% after first administration and 44% after
long-term treatment. Mean SPV decreased by $40%
in 40% of patients after first administration and in 4 of
7 subjects after long-term treatment. The remainder of
the patients showed a 10% to 30% decrease of mean
SPV after long-term treatment (see figure 1 and figure
2, A and B). In total, 50% of patients had a decrease of
mean SPV of $30% and 30% of patients of $50%
after the first administration of CHZ.
Effects of CHZ on VA. VA increased from 0.736 0.24
at baseline to 0.84 6 0.20 after first administration
and from 0.726 0.24 to 0.756 0.25 after long-term
treatment. There was a significant overall increase
(Friedman test with x2 statistics 5 7.00, p 5 0.047,
n 5 7) with a significant post hoc difference between
baseline and VA 90 minutes after administration of
CHZ (p 5 0.01) as well as between baseline and after
long-term treatment (p 5 0.02) (see figure 2C).
Effects of CHZ on postural sway. In condition 1, sway
path decreased from 1.68 6 0.95 m/min to 1.26 6
0.65 m/min 90 minutes after first administration and
from 1.36 6 0.63 m/min to 1.00 6 0.33 m/min
after long-term treatment. There was a marginal
significant overall decrease (Friedman test with x2
statistics 5 6.00, p 5 0.05, n 5 4) with a marginal
significant post hoc difference between baseline and
first administration (p 5 0.08) but no significance
between baseline and after long-term treatment (p5
0.12) (see figure 2D). In condition 2, sway path
decreased from 3.80 6 2.11 m/min to 3.17 6
2.07 m/min and from 4.31 6 2.29 m/min to
2.81 6 1.31 m/min. There was a significant overall
decrease (Friedman test with x2 statistics 5 6.50,
p 5 0.039, n 5 4) with a marginal significant post
hoc difference of sway between baseline and first
administration (p5 0.08) but no significance between
baseline and long-term treatment (p 5 0.435).
Side effects. All patients had normal blood test results.
Fifty percent of patients reported abdominal discom-
fort during the treatment period (patients 5, 7, 8, 9,
and 10). Patient 2 stopped treatment because of non-
compliance, patient 6 because of hospitalization for
formerly known atrial fibrillation, and patient 8
because of abdominal discomfort (see table 2). Regard-
ing the Vestibular Disorders Activities of Daily Living
Scale, there was no significant difference between the
scores of the patients at baseline and under treatment
Figure 1 Original recordings of vertical eye positions of different patients taking chlorzoxazone 500 mg 3
times a day
Original recording of the vertical eye position with mean slow-phase velocity of downbeat nystagmus of 3 different patients
(4, 7, and 10) at the different time points: before medication, 90 minutes after first administration of chlorzoxazone (CHZ)
500 mg 3 times a day (tid), and on medication with CHZ 500 mg tid for 1 or 2 weeks. *Nonresponder, treatment period of
1 week. Patients 7 and 10 (responder) received CHZ for 2 weeks.
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(p 5 0.691), but a positive tendency was shown in
some patients (3, 4, 5, 9, and 10).
DISCUSSION This observational proof-of-principle
pilot study showed that CHZ caused a significant
decrease of intensity of DBN and an improvement
of VA. Postural imbalance also improved. Forty per-
cent of patients had a decrease of$40% of mean SPV
during treatment with CHZ. In 60% of patients,
mean SPV decreased by .50% and in 70% by
.40% during treatment with 3,4-DAP.15 In compar-
ison, 40% of the patients receiving 4-AP showed a
decrease of mean SPV of .50%.1 Thus, CHZ at the
doses used might be less effective than aminopyri-
dines.1,2,15 Animal experiments suggest that CHZ
could be more effective than 4-AP.6,7
What is the assumed mechanism of CHZ in
DBN? In the tottering mouse, an animal model of
EA2, it was shown that CHZ (as well as 4-AP) can
prevent attacks (without an additive effect)6,7; oral
administration of CHZ also improved baseline motor
performance and reduced the severity and duration of
episodes of dyskinesia without producing any adverse
effects. Single-cell recordings revealed that in this ani-
mal model the firing rate of PCs is very irregular. The
loss of the precision of pace-making in EA2 is the
consequence of reduced activation of calcium-depen-
dent potassium channels by the smaller calcium cur-
rent. As shown in animal experiments, despite
contrasting pharmacologic effects of 4-AP (potassi-
um-channel blocker) and CHZ (unspecific SK-chan-
nel activation), both can restore the precision of pace-
making of PCs.7 For CHZ, the assumed pharmaco-
logic mechanism is an increase in the magnitude of
the potassium currents via SK channels.7 This may
also be relevant in DBN, which is assumed to be
caused by an impaired function of PCs in the floccu-
lus.4 In this observational study, patients received
CHZ, 500 mg 3 times a day. The US Food and Drug
Administration recommends an adult daily allowance
of 250–750 mg orally 3–4 times a day.10 With our
dosage, 50% of patients already reported abdominal
discomfort, which was probably due to the high ini-
tial dose. Perhaps patients would tolerate the drug
Figure 2 Effect of treatment with chlorzoxazone 500 mg 3 times a day in patients with downbeat nystagmus
Effect of chlorzoxazone (CHZ) on mean slow-phase velocity (SPV) (A, B), visual acuity (VA) (C), and posturography (D). Measurements performed at baseline,
90 minutes after medication, and on medication (1 or 2 weeks of CHZ 500 mg 3 times a day). Posturography only shown in condition 1: upright position with
eyes open and head inclined backward (30°) on firm ground. *On medication: 1 or 2 weeks under CHZ 500 mg 3 times a day. VA improved on medication.
Neurology 81 September 24, 2013 1155
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Table 2 Changes of clinical measurements on medication with CHZ 500 mg 3 times a day
Measurementa SPV (°/s)b
Sway path (m/min)
(cond. 1/cond. 2)c Visual acuity VDADL score Side effects
Patient 1
1 1.99 6 3.92 2.46/5.58 0.70 2.9 None
2 1.01 6 2.41 2.15/3.93 0.70
3 0.40 6 1.19 1.44/3.56 0.70 3.9
4
Patient 2
1 4.99 6 1.48 3.43/3.40 0.55 3.2 None
2 4.18 6 0.95 1.92/2.64 0.55
3 Stopped medication because of
noncompliance
4 5.13 6 1.44 0.55
Patient 3
1 1.09 6 0.72 1.18/2.67 1.00 2.4 None
2 0.10 6 0.35 1.16/2.39 1.00
3 0.26 6 0.36 1.03/2.00 1.00 1.6
4
Patient 4
1 7.04 6 5.94 0.89/2.56 0.50 4.1 None
2 6.72 6 0.92 0.45/0.95 0.90
3 5.99 6 0.76 0.74/1.76 0.80 3.9
4
Patient 5
1 4.06 6 0.57 1.06/7.76 0.58 4.0 Abdominal discomfort after
increase of dose (after 1 wk)
2 3.97 6 0.70 0.58/7.43 0.60
3 3.33 6 0.17 0.62/4.76 0.60 3.4
4 4.15 6 0.65 1.74/4.85 0.58
Patient 6
1 1.06 6 0.37 1.00/2.26 0.68 4.0 None
2 0.64 6 1.02 0.70 Stopped medication because of
hospitalization for formerly
known atrial fibrillation
3 1.66 6 0.68 1.30/2.95
4 0.70
Patient 7
1 1.23 6 0.70 1.76/2.85 0.68 3.8 Abdominal discomfort
2 0.81 6 0.60 1.55/2.55 0.89
3 0.11 6 0.40 0.70
4
Patient 8
1 1.39 6 1.10 1.42/2.54 1.00 5.9 Stopped the treatment because
of abdominal discomfort
2 0.06 6 1.00 1.00
3
4
Continued
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better with a slower titration. Furthermore, CHZ is not
only selective for SK channels but also activates large-
conductance potassium ion channels (BK channels).16
As selective drugs for SK channels become available,
they may be of superior therapeutic efficacy. As a selec-
tive positive modulator of calcium-activated potassium
channels with positive effects in mouse models of spi-
nocerebellar ataxia type 2 has become available, this
would therefore also be a potential candidate for the
treatment of DBN.17
This proof-of-concept pilot study has some limita-
tions. First, it was not a randomized placebo-controlled
clinical trial. Second, only one dosage was tested.
Third, the number of patients was low. Fourth, there
were not sufficient data for the washout period.
This study shows a significant effect of the nonse-
lective SK-channel activator CHZ in DBN. This is
thereby a new therapeutic principle that could be of
relevance not only for the treatment of DBN but also
for the treatment of other cerebellar disorders, e.g.,
EA218 or cerebellar gait disorders,19 which also respond
to aminopyridines. Thus, CHZ could be an alternative
symptomatic treatment option for patients with DBN,
in whom the use of aminopyridines is limited. It is
necessary to further evaluate the effects of CHZ on
DBN in a placebo-controlled, dose-finding trial with
additional outcome measures, in particular quality of
life.
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a Time periods: 1 5 baseline; 2 5 90 min after first administration; 3 5 after 1 or 2 wk under CHZ 500 mg 3 times a day;
4 5 after washout period without medication for at least 4 wk.
bMean 6 SD SPV of downbeat nystagmus of patients treated with CHZ at different time points.
c Cond. 1 5 upright position with eyes opened and inclined head on firm ground; cond. 2 5 upright position with eyes
opened and inclined head on foam ground.
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